<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-MCG25466-GHC-4H-HJF">
    <metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1785 IS: No Handouts for Drug Advertisements Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-05-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
        <distribution-code>II</distribution-code>
        <congress>119th CONGRESS</congress>
        <session>1st Session</session>
        <legis-num>S. 1785</legis-num>
        <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
        <action>
            <action-date date="20250515">May 15, 2025</action-date>
            <action-desc><sponsor name-id="S399">Mr. Hawley</sponsor> (for himself and <cosponsor name-id="S324">Mrs. Shaheen</cosponsor>) introduced the following bill; which
                was read twice and referred to the <committee-name committee-id="SSFI00">Committee
                    on Finance</committee-name></action-desc>
        </action>
        <legis-type>A BILL</legis-type>
        <official-title>To amend the Internal Revenue Code of 1986 to deny the deduction for
            advertising and promotional expenses for certain drugs.</official-title>
    </form>
    <legis-body display-enacting-clause="yes-display-enacting-clause">
        <section section-type="section-one" id="id9C60C7C7915742C2AC8E53F649178590">
            <enum>1.</enum>
            <header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>No Handouts for Drug Advertisements Act</short-title></quote>.</text>
        </section>
        <section section-type="subsequent-section" id="id8D9B72D3E5164AE5BEEFA68C42A4BA1F">
            <enum>2.</enum>
            <header>Disallowance of deduction for advertising and promotional expenses for certain
                drugs</header>
            <subsection id="idEFBA57D965B141029623D6D9F280E653">
                <enum>(a)</enum>
                <header>In general</header>
 <text display-inline="yes-display-inline">Part IX of subchapter B of chapter 1 of subtitle A of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text>
                <quoted-block style="OLC" display-inline="no-display-inline" id="id8f40758c27c9484f8646e6921e1b57d7">
                    <section id="id0D3C6EDA0156494885B148661B88E5BC">
                        <enum>280I.<?LEXA-Enum 280I.?></enum>
                        <header>Disallowance of deduction for direct-to-consumer advertising of
                            certain drugs</header>
                        <subsection id="idB9B6541BE875449A9D30E009479D3F2C">
                            <enum>(a)</enum>
                            <header>In general</header>
 <text display-inline="yes-display-inline">No deduction shall be allowed under this chapter for expenses relating to direct-to-consumer advertising of covered drugs for any taxable year.</text>
                        </subsection>
                        <subsection id="id7B678130CD764750BAA78A9F1F16314B">
                            <enum>(b)</enum>
                            <header>Direct-to-Consumer advertising</header>
 <text>For purposes of this section—</text> <paragraph commented="no" display-inline="no-display-inline" id="id2194c171f8194c828c1041fd7bfea34e"> <enum>(1)</enum> <header>In general</header> <text display-inline="yes-display-inline">The term <term>direct-to-consumer advertising</term> means any dissemination, by or on behalf of a covered entity, of an advertisement which—</text>
                                <subparagraph id="idA8D1E73D83BB4837B523F0C2DFB50D03">
                                    <enum>(A)</enum>
 <text>is in regard to a covered drug, and</text> </subparagraph> <subparagraph id="idE0D9BC713EA447F5B5D3FBC39553FB41"> <enum>(B)</enum> <text>primarily targeted to the general public, including through—</text>
                                    <clause id="id03A8A5F0105843999F0C06FBD5F67675">
                                        <enum>(i)</enum>
 <text>broadcasting through media such as radio, television, and telephone communication systems, direct mail, and billboards, and</text>
                                    </clause>
                                    <clause id="id8720001706FE4590B451EBF973E63631">
                                        <enum>(ii)</enum>
 <text>dissemination on the Internet or through digital platforms (including social media, mobile media, web applications, digital applications, mobile applications, and electronic applications).</text>
                                    </clause>
                                </subparagraph>
                            </paragraph>
                            <paragraph commented="no" display-inline="no-display-inline"
                                id="id14a15535b8584d448da57c277c04e335">
                                <enum>(2)</enum>
                                <header>Exception</header>
 <text display-inline="yes-display-inline">Such term shall not include an advertisement made through publication in journals and other periodicals.</text>
                            </paragraph>
                            <paragraph commented="no" display-inline="no-display-inline"
                                id="idbd15b0eb92a144449533d79c8c536d81">
                                <enum>(3)</enum>
                                <header>Other terms</header>
 <text display-inline="yes-display-inline">For purposes of this subsection—</text>
                                <subparagraph id="id12ba4ad229be43b9b359083f22ca9e5d">
                                    <enum>(A)</enum>
                                    <header>Covered entity</header>
 <text>The term <term>covered entity</term> means—</text> <clause id="idc479cad6e42440d88b863b2c3db7f38e"> <enum>(i)</enum> <text>a sponsor of a prescription drug product (as such term is defined in section 735(3) of the Federal Food, Drug, and Cosmetic Act), or</text>
                                    </clause>
                                    <clause id="id1b8f1a18f3b341d7a19e21689cd70914">
                                        <enum>(ii)</enum>
 <text>a person that owns an outsourcing facility (as such term is defined in section 503B(d)(4) of such Act), either directly or indirectly through a subsidiary.</text>
                                    </clause>
                                </subparagraph>
                                <subparagraph id="id5dc342b61e0046178d354d727bb624f9">
                                    <enum>(B)</enum>
                                    <header>Covered drug</header>
 <text>The term <term>covered drug</term> means—</text> <clause id="id829a1cba75d846b89e51dc41515b11fc"> <enum>(i)</enum> <text>a prescription drug product (as such term is defined in section 735(3) of the Federal Food, Drug, and Cosmetic Act), or</text>
                                    </clause>
                                    <clause id="idce7ff0923ab143ec9dcf5c1e31ac54d1">
                                        <enum>(ii)</enum>
 <text>a drug compounded in accordance with section 503A or 503B of such Act.</text>
                                    </clause>
                                </subparagraph>
                            </paragraph>
                        </subsection>
                    </section>
                    <after-quoted-block>.</after-quoted-block>
                </quoted-block>
            </subsection>
            <subsection id="id8449FEC2D4DD43199B6939F268C7BF0B">
                <enum>(b)</enum>
                <header>Conforming amendment</header>
 <text>The table of sections for such part IX of the Internal Revenue Code of 1986 is amended by adding after the item relating to section 280H the following new item:</text>
                <quoted-block style="OLC" id="ide50bc459-573e-403f-9eee-d038122a7c46">
                    <toc>
                        <toc-entry idref="id0D3C6EDA0156494885B148661B88E5BC" level="section">Sec.
                            280I. Disallowance of deduction for direct-to-consumer advertising of
                            certain drugs.</toc-entry>
                    </toc>
                    <after-quoted-block>.</after-quoted-block>
                </quoted-block>
            </subsection>
            <subsection id="id5989EA6032C74C01A77FBE2109F3B5E8">
                <enum>(c)</enum>
                <header>Effective date</header>
 <text>The amendments made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act, in taxable years ending after such date.</text>
            </subsection>
        </section>
    </legis-body>
</bill>

